Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,024.14
+0.34 (+0.03%)
Official Closing Price
Updated: 7:00 PM EST, Jan 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
The $5 Trillion Renaissance: How 2025 Redefined Global Deal-Making
January 23, 2026
The global financial landscape has undergone a seismic shift as 2025 closed with merger and acquisition (M&A) volumes surpassing a staggering $5 trillion. This "M&A Renaissance" marks a definitive end...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
↗
January 23, 2026
Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.
Via
The Motley Fool
Why a 15% Dividend Wasn’t Enough to Keep This $3.3 Million Position
↗
January 23, 2026
Trinity Capital provides venture debt and equipment financing to growth-stage tech companies seeking non-dilutive capital solutions.
Via
The Motley Fool
Topics
Regulatory Compliance
ELI LILLY & CO (NYSE:LLY) Offers a Durable Dividend with Strong Growth and Financial Health
↗
January 23, 2026
Via
Chartmill
Outfront Media Surges 40% in One Year, Then Gets Cut Loose Despite 'Exceptional Performance'
↗
January 23, 2026
This out-of-home advertising REIT connects brands with urban audiences through a broad network of billboard and transit assets.
Via
The Motley Fool
Topics
Regulatory Compliance
Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly
January 23, 2026
Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of...
Via
Finterra
Topics
Intellectual Property
Oral Wegovy Is Off To An Astronomical Launch. Will It Save Novo Nordisk Stock?
↗
January 23, 2026
Novo Nordisk stock rose Friday on report its oral Wegovy clocked 18,000 prescriptions in its second week on the market.
Via
Investor's Business Daily
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
↗
January 23, 2026
This biotech has candidates in late-stage clinical development.
Via
The Motley Fool
2 Mega-Cap Stocks to Target This Week and 1 We Find Risky
January 22, 2026
Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing...
Via
StockStory
The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era
January 22, 2026
Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally...
Via
MarketMinute
Topics
Economy
The Great Broadening: Why Early 2026 is Redefining the Market’s Winning Ticket
January 22, 2026
As the first month of 2026 draws to a close, the narrative that dominated Wall Street for the better part of three years—the undisputed reign of mega-cap technology—is rapidly fracturing. In its place,...
Via
MarketMinute
Topics
Economy
As Jensen Huang Preps to Visit China, How Should You Play Nvidia Stock?
January 22, 2026
Nvidia is a tech stock that has outpaced the broader markets by a significant margin over the past decade. Is NVDA still a good buy as Jensen Huang prepares to visit China?
Via
Barchart.com
Topics
Artificial Intelligence
Government
Supply Chain
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
January 22, 2026
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Initial Public Offering
Eli Lilly (LLY) Q2 2025 Earnings Call Transcript
↗
January 22, 2026
Eli Lilly (LLY) Q2 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
↗
January 22, 2026
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript
↗
January 22, 2026
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Eli Lilly and Co's Options Frenzy: What You Need to Know
↗
January 22, 2026
Via
Benzinga
ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY
January 22, 2026
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
Why Eli Lilly (LLY) Stock Is Up Today
January 21, 2026
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy designation for its...
Via
StockStory
Topics
Artificial Intelligence
Supply Chain
Beyond the Silicon: NVIDIA and Eli Lilly Launch $1 Billion ‘Physical AI’ Lab to Rewrite the Rules of Medicine
January 21, 2026
In a move that signals the arrival of the "Bio-Computing" era, NVIDIA (NASDAQ: NVDA) and Eli Lilly (NYSE: LLY) have officially launched a landmark $1 billion AI co-innovation lab. Announced during the...
Via
TokenRing AI
Topics
Artificial Intelligence
Economy
Intellectual Property
J&J Forecasts $100 Billion Milestone for 2026 as Trump Drug Pricing Deals Reshape the Pharma Landscape
January 21, 2026
NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026,...
Via
MarketMinute
Topics
Earnings
Economy
Government
Eli Lilly Stock Report: Momentum, Earnings And Analyst Targets
↗
January 21, 2026
Eli Lilly's stock is experiencing short-term volatility due to its proximity to a 52-week high and upcoming earnings, amid strong analyst support and mixed technical indicators.
Via
Talk Markets
Q3 Earnings Roundup: Zoetis (NYSE:ZTS) And The Rest Of The Branded Pharmaceuticals Segment
January 20, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years
↗
January 20, 2026
Via
Benzinga
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026?
↗
January 20, 2026
Despite a challenging year, the company has a lot to look forward to in the coming years.
Via
The Motley Fool
Is Oral Wegovy a Game Changer for Novo Nordisk?
↗
January 20, 2026
The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.
Via
The Motley Fool
AstraZeneca Signals End of an Era: Formal Move to NYSE Triggers Major Index Rebalancing
January 20, 2026
LONDON — January 20, 2026 — In a milestone moment for global capital markets, pharmaceutical giant AstraZeneca (NYSE: AZN) has officially filed its formal notice of voluntary withdrawal from the Nasdaq...
Via
MarketMinute
Topics
Regulatory Compliance
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026
↗
January 20, 2026
Via
MarketBeat
Prediction: This Healthcare Stock Could Soar by 72% in 2026
↗
January 19, 2026
And the share price appreciation could happen pretty soon.
Via
The Motley Fool
Down 55%, Should You Buy the Dip on Pfizer?
↗
January 19, 2026
Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?
Via
The Motley Fool
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.